{"id":"NCT00357734","sponsor":"AstraZeneca","briefTitle":"Iressa Follow-up Trial","officialTitle":"Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2006-07-27","resultsPosted":"2016-06-23","lastUpdate":"2016-08-30"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer","Breast Cancer"],"interventions":[{"type":"DRUG","name":"Gefitinib","otherNames":[]}],"arms":[{"label":"Gefitinib (ZD1839)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).","primaryOutcome":{"measure":"Number of Serious Adverse Events (SAEs)","timeFrame":"Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months)","effectByArm":[{"arm":"Gefitinib (ZD1839)","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":7,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":14},"commonTop":["NAUSEA","VOMITING","DIARRHOEA","PNEUMONITIS","DIZZINESS"]}}